Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2 …
PA Goepfert, B Fu, AL Chabanon… - The Lancet Infectious …, 2021 - thelancet.com
… achieve a robust immune response compared with antigen alone, … group as older adults are
less likely than younger adults to … study, with the aim of improving the reactogenicity profile. …
less likely than younger adults to … study, with the aim of improving the reactogenicity profile. …
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study
PA Goepfert, B Fu, AL Chabanon, MI Bonaparte… - medRxiv, 2021 - medrxiv.org
… the older adults than in younger adults. The unadjuvanted HD formulation generated similar
reactogenicity profiles … , 28-31 and compared to the reactogenicity profiles reported for other …
reactogenicity profiles … , 28-31 and compared to the reactogenicity profiles reported for other …
A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants
… Citation22 Dose ranging studies for PCV7 and PCV9 were only conducted in older adults in
… associated with acceptable safety and immunogenicity profiles in comparison to PCV13; it …
… associated with acceptable safety and immunogenicity profiles in comparison to PCV13; it …
A phase 1/2 randomized, double-blinded, placebo controlled ascending dose trial to assess the safety, tolerability and immunogenicity of ARCT-021 in healthy adults
… than at the 7.5 μg dose in older adults after a single dose (compared at Day 29 in the two-…
Taken collectively, the favorable safety and immunogenicity profiles support further clinical …
Taken collectively, the favorable safety and immunogenicity profiles support further clinical …
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1 …
W Guo, K Duan, Y Zhang, Z Yuan, YB Zhang… - …, 2021 - thelancet.com
… This study reported safety profile … studies indicated that the safety profile of vaccines against
the COVID-19 was similar or even better among older adults compared with younger adults …
the COVID-19 was similar or even better among older adults compared with younger adults …
… to a mammalian cell-based, MF59-adjuvanted, A/H5N1, pandemic influenza vaccine across four phase II/III clinical trials in healthy children, adults, and older adults
E Versage, E van Twuijver, W Jansen, A Theeuwes… - Vaccines, 2021 - mdpi.com
… Here we report immunogenicity and safety analyses of a mammalian cell-based, MF59-adjuvanted,
A/H5N1 vaccine across four clinical trials of similar design, comparing responses to …
A/H5N1 vaccine across four clinical trials of similar design, comparing responses to …
Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate—Two randomized Phase II clinical trials in 18 to 49 and≥ 50 …
S Pillet, J Couillard, S Trépanier, JF Poulin… - PloS one, 2019 - journals.plos.org
… tend to be lower in older as compared to younger adults [8, 9]. … was an observer-blind,
placebo-controlled, dose-ranging … and reactogenicity profiles of the QVLP were comparable to …
placebo-controlled, dose-ranging … and reactogenicity profiles of the QVLP were comparable to …
Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged≥ 50 years: a randomized …
…, UK Buchwald, V114-020 PNEU-TRUE study group - Vaccine, 2022 - Elsevier
… the older age groups (65–74 and ≥ 75 years) compared with … of age, sex, race, and ethnicity,
the immunogenicity profile … and the safety profile of the V114 combined lots compared with …
the immunogenicity profile … and the safety profile of the V114 combined lots compared with …
Comparative immunogenicity of enhanced seasonal influenza vaccines in older adults: a systematic review and meta-analysis
TWY Ng, BJ Cowling, HZ Gao… - The Journal of …, 2019 - academic.oup.com
… highlight the fact that further research is needed to compare new vaccine options, especially
… vaccine trials among older adults, we found comparable immunogenicity profiles among all …
… vaccine trials among older adults, we found comparable immunogenicity profiles among all …
… 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults
CA Shaw, A August, S Bart, PGJ Booth, C Knightly… - Vaccine, 2023 - Elsevier
… demonstrated favorable safety and reactogenicity profiles at all … Infants, older adults, and
immunocompromised individuals … note that direct comparison of the data in this study to those …
immunocompromised individuals … note that direct comparison of the data in this study to those …